January 14, 2022 News by Yedida Y Bogachkov PhD Trial of Cannabidiol-derived EHP-101 for Relapsing MS Enrolling Soon Emerald Health Pharmaceuticals will soon begin enrollment in a Phase 2a clinical trial investigating its cannabidiol-derived therapy EHP-101 in relapsing forms of multiple sclerosis (MS). The trial (NCT04909502) aims to recruit 50 patients, ages 18-55, with relapsing-remitting MS (RRMS) and active secondary progressive MS (SPMS).
March 10, 2021 News by Forest Ray PhD Emerald Health Preparing for Phase 2 Trial of EHP-101 for Relapsing MS Emerald Health Pharmaceuticals (EHP) is preparing for an international Phase 2 clinical trial testing EHP-101 for the treatment of multiple sclerosis (MS). The study will take place in about 20 locations in the U.S. and Australia, and is expected to include approximately 50 patients with relapsing forms of…
March 31, 2020 News by Marisa Wexler, MS Canada Rules EHP-101, Potential Cannabidiol Treatment, Not Controlled Substance EHP-101, a cannabidiol-derived investigational therapy being developed by Emerald Health PharmaceuticalsĀ (EHP)Ā to treat multiple sclerosis (MS), is not a controlled substance in Canada, the company announced. The active ingredient in EHP-101 is a derivative of cannabidiol, abbreviated CBD. This is one of the most well-known active compounds in…
August 27, 2019 News by Marisa Wexler, MS Phase 1 Clinical Trial of EHP-101 Concludes with Positive Safety Results The first in-human clinical trial of EHP-101, an investigational treatment for multiple sclerosis (MS) and systemic scleroderma (SSc), has been successfully completed,Ā Emerald Health PharmaceuticalsĀ (EHP) announced. EHP-101 demonstrated it was safe and well-tolerated in healthy volunteers, supporting further clinical development ofĀ EHP-101 in future Phase 2 clinical trials. The…
October 1, 2018 News by Diogo Pinto Cannabidiol-derived Treatment for MS, EHP-101, Enters Phase 1 Safety Study, Emerald Health Says Emerald Health PharmaceuticalsĀ announced that it has begun enrolling healthy volunteers for a Phase 1 clinical trial evaluating the safety and tolerability ofĀ EHP-101,Ā a potential cannabidiol treatment for multiple sclerosis (MS) and scleroderma. The randomized, double-blind, and placebo-controlled study (ACTRN12618001390279p) will Ā investigate the safety and pharmacokinetics (how…
August 24, 2018 News by Jose Marques Lopes, PhD Work Showing Potential of EHP-101 in MS Earns Research Award Carmen Navarrete, PhD, has been granted a Scientific Innovation Award for her post-doctoral presentation suggesting that theĀ multiple sclerosisĀ (MS) treatment candidateĀ EHP-101Ā is anti-inflammatory and may boost remyelination,Ā Emerald Health PharmaceuticalsĀ announced. Navarrete, a senior scientist at Vivacell Biotechnology Espana, a company owned by Emerald Health Research, received the award at the…
July 5, 2018 News by Jose Marques Lopes, PhD Cannabidiol Compound, EHP-101, Seen to Prevent Nerve Cell Damage in MS Mouse Model An investigational cannabidiol-derived compound called EHP-101 may help to boost remyelination, prevent nerve cell damage and lower the reactivity of microglia cells ā immune cells of the brain and spinal cord ā a Ā study inĀ mouse models of multiple sclerosis (MS) reports. EHP-101, being developed by Emerald Health…
March 23, 2018 News by Patricia Inacio, PhD Emerald’s Cannabinoid-derived EHP-101 Enhances Remyelination in 2 MS Mouse Models Emerald Health‘sĀ investigational cannabidiol-derived EHP-101 reduces neuroinflammation, the risk of loss of myelin, and nerve cell damage in two mouse models of multiple sclerosis (MS), a new study shows. These results support the potential therapeutic benefits of EHP-101 for MS, and Emerald Health Pharmaceuticals expects to launch a human…